AdreView™ Myocardial Imaging for Risk Evaluation - A Multicentre Trial to Guide ICD Implantation in NYHA Class II & III Heart Failure Patients With 25%≤LVEF≤35%
Phase of Trial: Phase III
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Iobenguane (Primary)
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms ADMIRE-ICD
- Sponsors GE Healthcare
- 21 Mar 2018 This trial has been Discontinued in Denmark (End date: 2018-02-21) and Spain.
- 15 Mar 2018 This trial has been Discontinued in Czech Republic.
- 13 Mar 2018 This trial has been Discontinued in Germany.